Biocytogen Launches “Nano 100 Project” to Develop Fully Human Nanobody Therapeutics for Over 100 Targets
21.2.2023 17:11:00 EET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced the launch of the “Nano 100 Project”, which aims to develop fully human nanobody drugs for over 100 targets. The Project combines Biocytogen’s proprietary fully human nanobody mouse, RenNano®, with its high-throughput in vitro and in vivo antibody screening platforms to develop fully human nanobody drugs on a large-scale.
Compared to traditional antibodies, nanobodies have smaller molecular weights and improved tissue penetration ability, which make them effective at infiltrating tumors and crossing blood-brain barriers. Additionally, nanobodies generally have longer CDR3 regions which enables them to recognize hidden epitopes better. Due to their simpler structure, nanobodies are more stable and easier to produce and engineer, making them ideal building blocks for complex modalities such as cell therapy, bispecific antibody and engager, multi-specific antibody, antibody drug-conjugate (ADC), and radionuclide antibody-conjugate (RAC).
After several years of endeavor, Biocytogen successfully engineered the RenNano mouse from its fully human antibody mouse, RenMab™. RenNano mouse possesses full human heavy chain variable regions and can produce heavy-chain-only antibodies (HCAbs). The variable regions of HCAbs, i.e., nanobodies, do not require in vitro humanization to develop drugs. Our research has shown that RenNano mouse can generate robust immune responses after immunizations by different antigens. HCAbs generated from the RenNano mouse have highly diverse CDR3 sequences and can recognize many epitopes with nM-level high affinities. In vitro and in vivo experiments have shown that RenNano-derived antibodies have favorable biological functions.
Based on RenNano’s excellent ability to discover fully human nanobodies, Biocytogen has launched the “Nano 100 Project”. The Project aims to develop fully human therapeutic nanobodies against over 100 targets, including tumor associated antigens (TAAs), GPCRs, immune-checkpoints, cytokines, and factors related to neurological diseases. Biocytogen is actively seeking collaborations with global pharmaceutical and biotech companies to combine its large-scale nanobody development abilities with collaborators’ expertise in nanobody-related therapeutics, such as cell therapies, bispecific and multi-specific antibodies, ADCs and RACs, to develop novel drugs with first-in-class and/or best-in-class potentials.
“We believe that with the ability to rapidly develop fully human nanobodies against selected targets, the ‘Nano 100 Project’ will provide our global partners with more diverse and better nanobody building blocks to accelerate the development of novel drugs,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Meanwhile, it is also an important supplement to Biocytogen’s Project Integrum.”
About RenNano®
Biocytogen's proprietary fully human nanobody generating mouse, RenNano, is one of the most comprehensive fully human antibody platforms in the world. Nanobody sequences generated from RenNano mice have the highest possible diversity and do not require antibody humanization, which saves time and cost and reduces the risk of failure during later stages of drug development. Additionally, compared to natural HCAb-producing species like camelids, mice are easier to breed and immunize, making them suitable for developing HCAbs on a large scale.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite®/RenNano® mice platforms for fully human monoclonal antibody, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMice™ licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230221005554/en/
Contact information
Biocytogen
Antibody platforms and antibody assets: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rapid Medical™’s DISTALS Trial Overwhelmingly Positive, Demonstrating Superior Reperfusion with TIGERTRIEVER™ 13 in Medium Vessel Stroke6.2.2026 21:30:00 EET | Press release
Rapid Medical™, a leading developer of active endovascular devices, today announced late-breaking results from the DISTALS multicenter, randomized controlled trial showing that TIGERTRIEVER™ 13 achieved superior brain tissue reperfusion with an excellent safety profile when compared with medical management in medium vessel occlusion (MVO) stroke. The findings were presented in the main closing session at the 2026 International Stroke Conference (ISC). Top-line results showed that the TIGERTRIEVER™ 13 arm demonstrated 3x more successful reperfusion without symptomatic intracranial hemorrhage (sICH) compared to medical management–86.3% vs 27.7% (p < 0.001). Notably, zero sICH events were reported in the randomized treatment arm treated with TIGERTRIEVER 13. By comparison, sICH rates reported with intravenous thrombolysis alone are higher, ranging from 2 – 6% in contemporary trials.1,2,3 “These results highlight what is possible when both the device and the trial are designed specifically
Al Barari Breaks Ground on The Cape, The Final Chapter of a Legacy6.2.2026 16:46:00 EET | Press release
Al Barari, Dubai’s pioneering nature-led community, has officially marked the groundbreaking of The Cape, its final signature residential development, celebrating two decades of visionary craftsmanship and a continued commitment to creating harmonious living environments rooted in nature. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260206475199/en/ Hazza Zaal, CEO of Al Barari Real Estate Group, alongside the Sales and Construction teams at The Cape Groundbreaking Ceremony, marking a milestone in Al Barari’s final signature development. (Photo: AETOSWire) The milestone ceremony signals the beginning of a landmark chapter for Al Barari, as The Cape represents the culmination of a 20-year legacy defined by intentional design, wellbeing-focused living, and immersive natural landscapes. Located within Dubai’s green heart, The Cape introduces an enriched lifestyle experience surrounded by lush botanical settings, gentle water
Quantfury and Sandwich Launch Commercial Series to Encourage Better Choices in Retail Trading6.2.2026 16:00:00 EET | Press release
Quantfury Trading Americas Limited (“Quantfury”), a global brokerage offering commission-free trading at real-time spot prices from major exchanges, has partnered with Sandwich, a leading creative agency for tech and product videos, to produce a Social Responsibility Commercial Series. The series of commercials incorporates clear, engaging storytelling to prompt viewers to think about common retail trading behaviors—especially high-energy marketing, gamification of speculation, and heavy focus on potential gains without equal attention to risks—and to choose more thoughtful, informed approaches. Lev Mazur, Founder of Quantfury, said: “It’s a pleasure to work with Sandwich, whose visual storytelling is outstanding. Since day one, Quantfury has aimed to question and improve the standard practices in the global retail trading industry.” Adam Lisagor, Founder of Sandwich, added: “A good investment is a story. Quantfury stood out by wanting to tell a real, interesting story first—rather tha
JSS: 2025 Sake Exports Grew Steadily, Reaching a Record 81 Markets6.2.2026 05:00:00 EET | Press release
Sake exports continued to expand in 2025 in both value and volume, with export destinations reaching a record 81 countries and regions. Export value increased 6% year on year to 45.9 billion yen, while export volume rose 8% to 33.55 million liters (3.73 million cases on a 9-liter basis), marking the second-highest export performance on record. The average export unit price per 750 ml bottle declined 2% year on year to 1,026 yen. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260205671686/en/ Sake Export Performance by Country (Top 10, 2025) Export value has nearly doubled since 2020, and the CAGR over the past five years reached 14%. This underscores sake’s position as a high-growth category globally. Asia remained the largest export destination, with export value totaling 28.8 billion yen, representing an 8% increase year on year and accounting for 63% of total export value. North America recorded exports of 12.4 billion ye
Canva Brings On-Brand Designs Directly into AI Assistants6.2.2026 01:00:00 EET | Press release
The future of work is being rewritten by AI, with professionals accomplishing in minutes what used to take hours. But there's been one persistent breaking point in AI assistants: generic visual outputs and off-brand colors that undermine AI speed with tedious manual cleanup. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260205384226/en/ Canva Today, that friction ends as Canva brings brand intelligence directly into the AI tools where modern day work happens most. Starting now, ChatGPT users can create designs completely tied to their Canva Brand Kit, making a company’s brand come to life visually and function as a living participant in AI workflows. This expansion marks the coming together of Canva and ChatGPT, two category-defining platforms, in a new way to make on-brand design more accessible and fluid. From client-ready pitch decks to social posts and professional-looking posters, the partnership continues to fuel Canv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom